These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35980261)

  • 1. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder.
    Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD
    J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
    Drevets WC; Furey ML
    Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
    Ellis JS; Zarate CA; Luckenbaugh DA; Furey ML
    J Affect Disord; 2014 Jun; 162():39-42. PubMed ID: 24767003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
    Furey ML; Khanna A; Hoffman EM; Drevets WC
    Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline mood-state measures as predictors of antidepressant response to scopolamine.
    Furey ML; Nugent AC; Speer AM; Luckenbaugh DA; Hoffman EM; Frankel E; Drevets WC; Zarate CA
    Psychiatry Res; 2012 Mar; 196(1):62-7. PubMed ID: 22349648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
    Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
    J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.
    Sarris J; Murphy J; Stough C; Mischoulon D; Bousman C; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH; Byrne GJ
    Psychopharmacology (Berl); 2020 Jan; 237(1):209-218. PubMed ID: 31712971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.